Leveraging Oral Solid Dose Technologies for the Development and Manufacturing of Potent Treatments

Life Sciences, Pharmaceutical, Drug Discovery & Development,
  • Thursday, April 27, 2023

The discovery of new treatment modalities for oncology, neurology and rare diseases has seen a shift away from broad spectrum drugs in favor of more targeted, and often more potent drugs. One driver contributing to this growth is the rise of highly selective biological targeting mechanisms, which are capable of more precisely attacking only specific sites of action and can therefore be more potent than non-targeted treatments. However, converting such highly potent drug substances into drug products comes with formulation and process development challenges. With state-of-the-art containment and appropriate delivery technologies, such as oral solid dose technologies, highly potent drug products can be safely developed and manufactured into effective treatments.

Join this panel of industry experts as they delve into the driving forces that have created the recent surge in treatments for oncology and rare disease. Attendees will gain insights into the challenges and opportunities presented in the development and manufacturing of potent treatments. The featured speakers will discuss how the choice of appropriate oral solid dose technologies can help overcome development and manufacturing obstacles. Attendees will discover how industry leaders have utilized oral solid dose technologies through real-world case studies.


Dr. Andreas Flückiger, Pharmaceutical Industry

Dr. Andreas Flückiger, Occupational Toxicology and Containment for the Pharmaceutical Industry

Dr. Flükieger is experienced in occupational health and toxicology, as well as process containment for pharmaceutical companies, with over 30 years as Chief Occupational Health Officer at F. Hoffmann-La Roche Ltd. Dr. Flükieger is currently consulting part-time and teaching while also holding a professorship at the Viennese Academy of Occupational Medicine and Prevention. Dr. Flükieger is actively involved in various task forces of ASTM, ISPE and ECA.

Message Presenter
Anshul Gupte, Catalent

Anshul Gupte, PhD, RAC-Drugs, Senior Director, Scientific and Technical Affairs, Catalent

Anshul Gupte is responsible for technical and scientific oversight of client projects. He works across various functional teams in RFP considerations and scope of work development, proposal delivery, client and prospective client meetings and contributes to the company’s thought leadership agenda. Most recently Anshul served as Senior Director, Drug Product Development for Mayne Pharma in Australia. Previously he worked with Metrics Contract Services in Greenville as Director of Pharmaceutical Development. Anshul holds a Bachelor of Pharmacy from the RGPV University, Bhopal, India, a Master of Science in Pharmaceutical Sciences from Temple University and a Doctorate in Pharmaceutical Sciences from the University of Kentucky.

Message Presenter

Who Should Attend?

  • Pharmaceutical Development Groups
  • Operations and Facility Personnel
  • Quality Engineering and Quality Assurance Teams
  • Environmental, Safety and Health Groups
  • Procurement
  • Consultants

What You Will Learn

  • Hear industry experts give an overview of the trends, challenges and opportunities for high potency drug products
  • Gain an understanding of the oral delivery technologies that are best suited for potent compounds
  • Learn the benefits of integrated development and manufacturing solutions

Xtalks Partner


Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000+ partner programs and annually launches over 150 new products, and its flexible manufacturing platforms at 50+ global sites supply over 80 billion doses of nearly 8,000 products. Catalent is headquartered in Somerset, New Jersey.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account